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Abstract
 Background—Dimethyl fumarate (DMF) alters the phenotype of circulating immune cells 
and causes lymphopenia in a subpopulation of treated MS patients.
 Objective—To phenotypically characterize circulating leukocytes in DMF-treated MS 
patients.
 Methods—Cross-sectional observational comparisons of peripheral blood from DMF-treated 
MS patients (n=17 lymphopenic, 24 non-lymphopenic), untreated MS patients (n=17) and healthy 
controls (n=23) that was immunophenotyped using flow cytometry. Longitudinal samples were 
analyzed for 13 DMF-treated patients.
 Results—Lymphopenic DMF-treated patients had significantly fewer circulating CD8+ and 
CD4+ T-cells, CD56dim NK cells, CD19+ B-cells and plasmacytoid dendritic cells compared to 
controls. CXCR3+ and CCR6+ expression was disproportionately reduced among CD4+ T-cells 
while the proportion of T regulatory cells was unchanged. DMF did not affect circulating CD56hi 
NK-cells, monocytes or myeloid dendritic cells. Whether lymphopenic or not, DMF-treated 
patients had a lower proportion of circulating central and effector memory T cells and concomitant 
expansion of naïve T cells compared to controls.
 Conclusions—DMF shifts the immunophenotypes of circulating T cells, causing reduction of 
memory cells and relative expansion of naïve cells regardless of absolute lymphocyte count. This 
may represent one mechanism of action of the drug. Lymphopenic patients had disproportionate 
loss of CD8+ T cells, which may affect their immunocompetence.
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 Introduction
Dimethyl fumarate (DMF) was FDA approved in 2013 for the treatment of relapsing 
multiple sclerosis (MS). In clinical trials, absolute lymphocyte counts (ALC) typically 
dropped by about 30% and a subset of patients (5-6%) developed severe lymphopenia with 
an ALC of <500 while on drug (1, 2). DMF-induced lymphopenia is even more common in 
clinical practice. In a small clinical cohort, half of patients treated for >12 months developed 
lymphocyte counts below the lower limit of normal; CD8+ T cells were preferentially lost 
(3). In another study, older patients (over 55 years of age), patients with lower baseline ALC, 
and patients with recent natalizumab (NTZ) exposure appeared to be at higher risk of 
lymphopenia (4).
The mechanism by which DMF acts to reduce relapses in MS is multifactorial and may 
include lymphocyte depletion. Indeed, MS is viewed as a lymphocyte-mediated disease (5). 
Depleting autoreactive cells and inhibiting their access to the CNS are known mechanisms 
for other MS disease modifying therapies (DMTs).
Nevertheless, lymphopenia is also a risk factor for infection. While opportunistic infections 
are uncommon, progressive multifocal leukoencephalopathy (PML) has been identified 
among patients taking DMF and related fumarate compounds (6-9). Affected patients were 
lymphopenic and had been treated with fumarates for years. Fatal West Nile encephalitis, 
disseminated varicella zoster, and Kaposi sarcoma have also been associated with fumarates 
(10-12).
A better understanding of DMF-induced lymphopenia is necessary to understand the 
mechanism of this immune-modulating drug and to predict and manage complications that 
may arise with long term use. To this end, an extensive immunophenotypic analysis of blood 
leukocytes in lymphopenic and non-lymphopenic DMF-treated patients compared to 
untreated MS patients and healthy individuals was performed.
 Methods
 Subject selection
This was a cross-sectional, observational study. We enrolled 41 MS patients who had been 
stable on DMF (Tecfidera, Biogen, Weston, MA; 240mg p.o. bid) for ≥6 months, including 
17 patients with grade 2-3 lymphopenia (ALC of <800 cells/μl) according to the common 
terminology criteria for adverse events (http://evs.nci.nih.gov/ftp1/CTCAE/
CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf). Lymphopenic patients were 
specifically recruited. We also recruited 17 MS patients who were not taking DMT and 23 
healthy volunteers to serve as controls. Patients who had received steroids within the last 3 
months were excluded. Blood samples were drawn between 8:30 AM and 1:30 PM. EDSS 
scores were retrospectively determined for MS patients based on clinical documentation at 
the time of enrollment. Serial specimens were obtained from 13 subjects. The time between 
blood draws was 4-6 months (median 6 months). Two patients made their initial donation 
after taking DMF for only 3-4 months; data from those initial samples were included only in 
the longitudinal portion of the analysis. This study was approved by the Washington 
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University Human Research Protection Office and all subjects provided written informed 
consent.
 Leukocyte phenotyping
Fresh whole blood was labeled with CD25, CD45RA, CD45RO, CD86 (clone FUN-1), 
CCR7 (clone 150503; all from BD Biosciences), Foxp3 (clone 259D), CXCR3 (clone 
G025H7), BDCA-2 (clone 201), BDCA-4 (clone 12C2), Lin-1, CD1c (clone L161; all from 
Biolegend), CCR6 (clone R6H1), CD56 (clone CMSSB), C14 (clone 61D3), CD3 (clone 
SK7), CD62L (clone DREG-56; all from eBioscience), HLA-DR, CD4 and CD8 (Beckman 
Coulter). Fluorescent eBeads (eBioscience) were added to allow calculation of absolute cell 
numbers and flow cytometry was performed using a Beckman Coulter Gallios instrument 
with 10 fluorescent channels.
 Statistical analysis
Statistical analysis was performed using GraphPad Prism 6 (La Jolla, CA) and SPSS version 
23.0 (IBM Corp, Armonk, NY). Because most of the data were not normally distributed, 
comparisons between groups were performed using Kruskal-Wallis ANOVA with Dunn's 
multiple comparison test for differences between groups. We also performed multiple linear 
regression analyses to control for age between the groups. Results were considered 
significant at p<0.05.
 Results
Flow cytometric analysis of peripheral immune cells was performed in 41 DMF treated MS 
patients, 17 untreated MS controls and 23 healthy controls (HC) (Supplementary Table 1). 
DMF treated MS patients included 17 patients with grade 2-3 lymphopenia based on routine 
laboratory testing (DMF-L; mean ALC 594 cells/μl, range 300-800) and 24 patients with 
normal lymphocyte counts (DMF-N; mean ALC 1493 cells/μl, range 900-3300). Groups had 
similar baseline demographics including age (mean 46, range 25-69), sex, and EDSS 
(median 2.75, range 0-6.5) (Supplementary Table 1). There were no significant differences 
between DMF groups in terms of prior treatments (most patients had transitioned to DMF 
from interferons or glatiramer) or number of prior disease modifying therapies. 
Lymphopenic patients had a slightly longer exposure to DMF compared to non-lymphopenic 
patients and had carried a diagnosis of MS for longer than untreated MS controls 
(Supplementary Table 1). The duration of MS did not differ between lymphopenic and non-
lymphopenic DMF treated patients.
Absolute cell counts for all T-lymphocyte populations, including CD4+, CD8+ and T 
regulatory cells (T-regs; CD4+ CD25+ Foxp3+), were significantly reduced in lymphopenic 
DMF-treated patients compared to HC and MS controls (Figure 1A-C, Table 1). Non-
significant trends for lower T-lymphocyte counts in non-lymphopenic DMF-treated patients 
compared to the control groups were observed. Despite reduced absolute numbers of 
circulating T-regs among lymphopenic patients, the proportion of T-regs did not change 
between treatment groups (Table 2, Figure 1B, H). Relative reduction in CD8+ T-cells was 
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particularly marked in lymphopenic patients, evidenced by an increased CD4/CD8 ratio 
(Figure 1I, Table 1).
Among other immune cell subsets, lymphopenic DMF-treated patients had significantly 
fewer CD56dim natural killer cells (NK cells; CD3− CD56dim) compared to HC and MS 
controls. Numbers of CD56dim NK cells were also reduced in non-lymphopenic DMF 
treated patients compared to HC (Figure 1E). CD19+ B cells and plasmacytoid dendritic 
cells (pDCs; Lin1− HLADR+ CD1c− BDCA4+ BDCA2+) were reduced compared to 
controls in lymphopenic DMF-treated patients (Figure 1D, G). There were no differences in 
the absolute numbers of CD14+ monocytes, CD56hi NK cells, or myeloid DCs (Lin1− 
HLADR+ CD1c+ BDCA4− BDCA2−) compared to controls (Figure 1F, H; Table 1).
Given the variable treatment intervals, we subdivided DMF treated patients into those treated 
for 6-12 months (n=11 for DMF-N and n=5 for DMF-L) and those treated for >12 months 
(n=16 for DMF-N and n=12 for DMF-L; three patients contributed samples to both the 6-12 
month subgroup and the >12 month subgroup). No significant differences between these 
groups were observed for any lymphocyte subset (data not shown).
Within CD4+ and CD8+ lymphocyte subsets, we assessed the proportion of naïve, central 
memory (TCM) and effector memory (TEM) populations. DMF treatment was associated 
with relative expansion of the CD4+ and CD8+ naïve (CD45RA+ CCR7+) T cell subset and 
loss of TCM(CD45RA− CCR7+) and TEM(CD45RA− CCR7−) subsets for both lymphopenic 
and non-lymphopenic patients (Table 2, Figure 2A, B). We confirmed these findings using 
an alternate method of identifying TCM(CD45RO+ CD62L+) and TEM(CD45RO+ CD62L−). 
Using this definition, we again observed that the fractions of circulating TCM and TEM were 
significantly decreased for both groups of DMF-treated patients when compared to healthy 
and MS controls with concurrent relative expansion of naïve T cell populations 
(Supplementary Figure 1). Analyses of serial blood samples from a subset of our cohort 
demonstrated that these lymphocyte populations were generally stable over time (Figure 2 
C-D). A trend for recovery of the effector memory CD4+ T-cell population with time was 
observed in some subjects; all other subsets were unchanged during ongoing DMF exposure.
L-selectin (CD62L) is downregulated on T cells as they differentiate and become activated. 
Moreover, low numbers of circulating CD62L+ CD4+ T cells may be a biomarker for PML 
risk among NTZ treated patients (13). Thus, circulating CD62L+ CD4+ lymphocytes were 
compared between groups. Both lymphopenic and non-lymphopenic DMF-treated patients 
had expansion of the CD62L+ CD4+ lymphocyte population compared to untreated MS 
controls and HC (Table 2).
Our cohort included a wide age range, and age has previously been linked to DMF-induced 
lymphopenia (4). Therefore, we performed multiple linear regression models to account for 
age. After controlling for age, DMF treatment remained a significant predictor for numbers 
of CD4+ and CD8+ T-cells, T-reg, CD56dim NK (p≤0.001 for all), and pDC (p=0.004) as 
well as for percentages of CD4+ and CD8+ naïve, TCM and TEM (p<0.001 for all). However, 
DMF was not a significant predictor for CD19+ cell number after controlling for age 
(p=0.123). Interestingly, age was an independent predictor of CD8+ (including naïve and 
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TEM subsets) and plasmacytoid DC cells but did not contribute to other circulating 
lymphocyte subpopulations.
CXCR3 has been considered a surrogate marker for CD4+ T-helper (Th) 1-type pro-
inflammatory lymphocytes, while CCR6 has been considered a surrogate marker for IL-17 
producing Th17-type lymphocytes. Both subsets are thought to be pathogenic in MS 
(14-16). We examined expression of these chemokine receptors on CD4+ and CD8+ T cells. 
Among lymphopenic DMF-treated patients, a smaller fraction of circulating CD4+ T cells 
expressed CXCR3 and CCR6 when compared to controls (Table 2; Figure 3A-B). Despite 
reductions in CD8+ numbers with DMF treatment, there were no changes in the proportions 
of CXCR3 or CCR6-expressing CD8+ T cells (Figure 3C-D).
 Discussion
We performed extensive immune phenotyping of peripheral immune cells in DMF-treated 
patients with and without lymphopenia as well as in HC and untreated MS controls and 
demonstrated reductions of multiple circulating immune cell subsets, particularly CD4+ and 
CD8+ T lymphocytes, among lymphopenic DMF-treated patients. Moreover, we 
demonstrated that DMF shifts the immunophenotype of circulating T cells, causing selective 
reductions of circulating central and effector memory CD4+ and CD8+ lymphocytes 
regardless of absolute lymphocyte counts. These data may help elucidate the mechanism of 
action for DMF as well as provide additional information about the immunocompetence of 
patients taking DMF.
Memory T lymphocytes are responsible for mounting a rapid, robust immune response to a 
previously encountered antigen. In the healthy immune system, antigen-specific TEM rapidly 
migrate to areas of infection or inflammation and have immediate effector function while 
TCM home to secondary lymphoid tissue, proliferate in response to antigenic stimulation and 
differentiate into TEM. Presumably, the majority of autoreactive T cells in MS are memory 
cells (17). Indeed, this is the premise behind recent trials of stem cell transplant in MS; by 
eradicating autoreactive memory populations and “rebooting” the immune system using 
autologous stem cells, patients have achieved long lasting remission and in some cases, 
reversal of disability (18, 19). Depleting memory T cells may therefore be a key mechanism 
for DMF efficacy analogous to an established mechanism of action for other MS therapies. 
Fingolimod depletes circulating naïve T cells and TCM (20) and the number of circulating 
TCM is a biomarker of response to fingolimod (21). Similarly, we have now shown that DMF 
reduces circulating TCM in MS patients. Unlike fingolimod, DMF expands the proportion of 
naïve T cells in the circulation and reduces TEM.
Reduction in circulating CD62L+ CD4+ lymphocytes has been proposed as a possible 
biomarker of PML risk for NTZ treated patients. Schwab and colleagues showed that this T 
cell subset was markedly diminished in NTZ-treated patients who subsequently developed 
PML when compared to controls and to NTZ-treated patients who did not develop PML 
(13). Given recent concerns about possible PML risk with DMF therapy, we assessed this T 
cell population among our cohort and found that CD62L+ CD4+ lymphocytes were relatively 
expanded among patients taking DMF. The role of L-selectin (CD62L) in MS is 
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controversial (22); it is an adhesion molecule that is downregulated as T cells mature and 
become activated (23). The expansion of CD62L+ populations in DMF-treated individuals 
thus parallels the expansion of naïve T cells. Whether loss of circulating CD62L+ CD4+ T 
cells is a biomarker for PML risk in DMF-treated patients deserves investigation. Indeed, the 
mechanism of DMF-induced T cell redistribution requires further study. In vitro data suggest 
that fumarates induce T cell apoptosis as well as impair lymphocyte proliferation and DC 
differentiation (24, 25). Future studies should investigate lymphocyte differentiation and 
maturation in patients taking DMF to further explore the phenomenon of drug-induced T 
lymphocyte redistribution.
We observed loss of several other immune subsets in DMF-treated patients when compared 
to controls. NK cells are subdivided into the CD56dim population, which has enhanced 
killing activity, and the CD56hi population, which secretes large amounts of cytokines but is 
not cytotoxic (26). Recent work has illustrated that CD56hi NK-cells are immunoregulatory; 
these are expanded by daclizumab, a monoclonal antibody currently undergoing trials for 
MS. CD56hi NK cell expansion is thought to contribute to the efficacy of daclizumab in MS 
(27). Patients taking DMF maintained this immunomodulatory CD56hi population. In 
contrast, CD56dim NK-cells were decreased in both lymphopenic and non-lymphopenic 
patients. Little is known about the role of CD56dim NK cells in MS, although one study 
suggested that this population expands in progressive MS (28).
We also observed a modest decrease in pDCs among lymphopenic DMF-treated patients 
compared to HC. This versatile cell type performs many immune functions including 
production of type 1 interferons; pDCs may be either immunogenic or tolerogenic, 
depending on the specific microenvironment (29). pDCs have been identified in MS lesions, 
but their role in the disease remains controversial (30). Further study is needed to confirm 
these findings and to explore the possible functional consequences.
In addition to altering T-lymphocyte subpopulations and depleting multiple types of 
circulating immune cells, DMF selectively reduced the proportion of circulating CXCR3+ 
CD4+ and CCR6+ CD4+ cells, but not T-regs, among lymphopenic patients. The CXCR3+ 
CD4+ population was also reduced in non-lymphopenic DMF-treated patients. These 
chemokine receptors are sometimes considered surrogate markers for Th1 and Th17 type 
pro-inflammatory lymphocytes, respectively; both T cell subsets have been implicated in MS 
pathogenesis (14-16). Selective depletion of Th1 and Th17 cells would be expected to be 
protective in MS and could contribute to the therapeutic effect of DMF. Nevertheless, 
despite the loss of CXCR3+ and CCR6+ cells among lymphopenic patients taking DMF, 
these patients have not shown a superior clinical response to the drug to date (4, 31)
Spencer and colleagues recently addressed DMF-induced immunophenotypic changes in a 
small cohort of patients that was followed longitudinally (3). Like us, they found a 
disproportionate reduction in CD8+ T cells relative to CD4+ T cells. They also reported 
time-dependent reductions in CD8+, CD4+ and CD19+ lymphocytes, with no alteration in 
the levels of CD56+ NK cells, monocytes and other WBC types. They did not examine T cell 
subsets (i.e. regulatory or memory T cell populations). Our cross-sectional observational 
study covered a larger group of subjects and was designed to include DMF-treated patients 
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with and without clinical lymphopenia as well as untreated MS controls and HC. We 
confirmed reductions in CD8+ T cells and CD4+ T cells as well as a slight reduction in 
CD19+ B cell numbers when compared to controls; after controlling for age, however, DMF 
treatment did not affect CD19+ numbers. Although Spencer et al. demonstrated a reduction 
in CD19+ cells over time, the absolute cell numbers typically remained within normal limits. 
Thus, the apparent discrepancy between our results is likely attributable to the longitudinal 
versus cross-sectional study design. Our phenotyping of T-regs, naïve, central memory and 
effector memory T cell subsets, CD56hi vs CD56dim NK cells and dendritic cells greatly 
extends the findings previously reported.
Few opportunistic infections have been reported with DMF. Despite this, the observed 
reductions of several WBC types suggest that clinicians should maintain vigilance. Concerns 
remain about the long term safety of reducing T lymphocytes in general and memory T cells 
in particular. CD4+ T cell depletion is associated with a variety of opportunistic infections 
(32, 33). CD8+ T cells are major effectors of viral immunity and contribute to immune 
surveillance of the CNS (34). It is possible that viral infections may become more prevalent 
in the setting of DMF-associated CD8+ T cell reduction; recent reports of West Nile 
encephalitis and disseminated varicella zoster in DMF treated patients substantiate this (10, 
11). Redistributing naïve and memory T lymphocyte populations relative to one another is 
also likely to have functional consequences (35) .
Our data are limited by the cross sectional, observational design of this study. Although 
serial data from a subset of our study group on DMF for 3 months or more demonstrated 
stability of lymphocyte subsets during DMF therapy, pre-treatment immunophenotyping was 
not available. Examination of the recovery of immune cell phenotypes after discontinuation 
of DMF over time would have been desirable as well, but these data were not interpretable 
as patients who stopped DMF due to lymphopenia typically began other DMTs immediately 
thereafter. Moreover, we assessed circulating lymphocytes. It is possible that DMF alters 
immune cell compartmentalization and that lymphocytes are merely being redirected to 
another location rather than being permanently lost. Additional work will need to identify 
the mechanisms of DMF-induced lymphopenia and selective memory T cell loss as well as 
any functional consequences.
In summary, we have shown that DMF induces redistribution of CD4+ and CD8+ naïve and 
memory T cells with relative loss of circulating TCM and TEM cells in patients exposed to 
the drug, regardless of their absolute lymphocyte count. Moreover, it causes loss of CD4+ 
and CD8+ T-lymphocytes from the bloodstream, with particular reductions of Th1 and Th17-
like cells, in a subset of MS patients.
 Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Frequencies of circulating leukocytes in DMF treated MS patients compared to 
controls
Absolute numbers of immune subsets were compared among healthy controls (n=23), 
untreated MS controls (n=17), DMF-treated patients without lymphopenia (DMF-N; n=24), 
and lymphopenic DMF-treated patients (DMF-L; n=17) using flow cytometry (A-G). 
CD4/CD8 ratio (I) was calculated based on % of total CD3+ gated cells. Error bars represent 
mean and standard deviation. Kruskal Wallis ANOVA with Dunn's multiple comparison test 
was used to compare between groups. T-reg: T regulatory cell; NK: natural killer cell; DC: 
dendritic cell * p<0.05, ** p<0.01, *** p<0.001; **** p<0.0001
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Figure 2. DMF effects on naïve and memory T cell distribution
Proportions of CD4+ and CD8+ naïve (CD45RA+ CCR7+), central memory (CD45RA− 
CCR7+) and effector memory (CD45RA− CCR7−) T cells were identified using flow 
cytometry. Distributions for each subset are shown in A-B. A subset of DMF-treated patients 
(n=13) provided longitudinal samples, and the naïve and memory T-cell distributions are 
shown over time (C-D). Solid lines represent the group mean for MS control group and 
dotted lines represent the group mean for the healthy control group. Stars represent samples 
obtained from lymphopenic patients (C-D). Error bars represent mean and standard 
deviation. Kruskal Wallis ANOVA with Dunn's multiple comparison test was used to 
compare between groups. * p<0.05, ** p<0.01, *** p<0.001; **** p<0.0001.
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Figure 3. DMF effects on circulating CXCR3+ and CCR6+ on T cells
Expression of the Th1 chemokine receptor CXCR3 and the Th17 chemokine receptor CCR6 
was determined on CD4+ (A, B) and CD8+ (C, D) lymphocytes. Error bars represent mean 
and standard deviation. Kruskal Wallis ANOVA with Dunn's multiple comparison test was 
used to compare between groups. * p<0.05, ** p<0.01, *** p<0.001; **** p<0.0001.
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Table 1
DMF effects on absolute numbers of circulating leukocytes.
Cells/μl
Markers Examined by Flow Cytometry (No. of 
subjects)
Healthy Controls (n=23) MS Controls (n=17) DMF-N (n=24) DMF-L (n=17)
T-lymphocytes
CD3+CD4+ 474 (216-822) 482 (105-959) 346 (150-709) 140 (35-302)4, d
CD4+ CD25+ Foxp3+ (T-reg) 34 (5-77) 37 (14-85) 23 (7-73) 12 (4-42)3, d
CD3+CD8+ 145 (60-320) 140 (66-295) 105 (27-301) 20 (5-129)4, d
CD4/CD8 (mean, SD) 3.5 (2.3) 3.9 (2.6) 4.6 (2.8) 6.6 (3.2) 2, a
B-lymphocytes
CD19+ 122 (46-247) 131 (31-257) 129 (54-311) 79 (31-193)1, a
Monocytes
CD14+ 176 (65-330) 167 (59-313) 122 (29-352) 145 (56-242)
NK cells
CD3− CD56lo 111 (34-272) 88 (28-396) 51 (19-136)2 46 (14-98)4, a
CD3− CD56hi 8 (2-18) 6 (1-13) 9 (3-20) 8 (2-19)
Dendritic cells
Lin1− HLADR+ CD1c− BDCA4+ BDCA2+ 
(Plasmacytoid)
2 (1-4) 2 (0-4) 2 (0-5) 1 (0-2)2, a
Lin1− HLADR+ CD1c+ BDCA4− BDCA2− 
(Myeloid)
4 (0-8) 4 (1-14) 3 (0-9) 3 (0-8)
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Table 2
DMF effects on circulating T-cell subpopulations.
Percent
Markers Examined by Flow Cytometry (No. of 
subjects)
Healthy Controls (n=23) MS Controls (n=17) DMF-N (n=24) DMF-L (n=17)
CD4+ Subpopulations
CD4+ CD25+ Foxp3+ (T-reg) 7 (4-11) 8 (3-12) 7 (4-12) 8 (5-17)
CD4+ CD45RA+ CCR7+ (naïve) 42 (27-65) 35 (9-70) 57 (27-87)a 70 (30-82)2, d
CD4+ CD45RA− CCR7+ (TCM) 40 (21-58) 38 (25-63) 24 (11-62)1, a 16 (2-48)4, d
CD4+ CD45RA− CCR7− (TEM) 7 (3-13) 7 (3-17) 4 (1-18)a 3 (1-10)3, c
CD3+CD4+CXCR3+ 40 (21-50) 39 (20-75) 25 (14-58)2, a 23 (13-49)3, b
CD3+CD4+CCR6+ 13 (2-20) 11 (1-32) 7 (2-46) 5 (3-22)a
CD4+ CD62L+ 86 (80-94) 88 (79-94) 95 (76-99)3, b 97 (85-98)4, c
CD8+ Subpopulations
CD8+ CD45RA+CCR7+ (naïve) 39 (18-70) 36 (5-63) 58 (17-88)1, b 46 (20-88)
CD8+ CD45RA− CCR7+ (TCM) 10 (2-23) 12 (2-41) 4 (1-27)2, b 2 (1-17)4, d
CD8+ CD45RA− CCR7− (TEM) 26 (8-49) 22 (9-35) 10 (4-47)4, b 12 (1-46)1
CD3+CD8+CXCR3+ 87 (73-95) 90 (63-96) 86 (55-98) 88 (84-96)
CD3+CD8+CCR6+ 11 (4-32) 8 (2-23) 10 (1-48) 10 (3-27)
CD8+ CD62L+ 61 (37-86) 68 (31-81) 80 (39-97) 76 (41-97)
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